Lee Kyoung Hwa, Kim Yeong Ouk, Dho So Hee, Yong Jen J H, Oh Hyun-Seok, Lee Je Hee, Yang Seung-Jo, Cha Inseong, Chun Jongsik, Lee Eun Hwa, Jeong Su Jin, Woo Wonjin, Choi Jae-Phil, Han Sang Hoon, Choi Gloria B, Huh Jun R, Kim Lark Kyun, Song Young Goo
Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
CJ Bioscience, Inc., Seoul, Republic of Korea.
Front Cell Infect Microbiol. 2024 Nov 28;14:1455295. doi: 10.3389/fcimb.2024.1455295. eCollection 2024.
Coronavirus disease 2019 (COVID-19) alters the gut microbiome. This study aimed to assess the association between the disease severity of COVID-19 and changes in stool microbes through a seven-month follow-up of stool collection.
We conducted a multicentre, prospective longitudinal study of 58 COVID-19 patients and 116 uninfected controls. Differences in the gut microbiota were analysed using 16S ribosomal RNA sequencing. The first stool samples were collected at an early convalescent phase of COVID-19, and the second sample was collected at least seven months after COVID-19 infection.
At the order level, and decreased, while and increased in the COVID-19 group compared to the controls. Alpha diversity also decreased in COVID-19 patients compared to controls, with imperfect recovery of the gut microbiome after seven months. The compositional change in the gut microbiome between the early and late convalescent phases was largest in the moderate and severe groups. The severity of COVID-19 was the most influential clinical variable for microbiome composition (Sum of Sqs = 0.686, = 0.006), and its effect persisted even after partialling out other effects such as antibiotic use and age. Thus, our study indicates a possible interaction between respiratory viral infection and the composition of the gut microbiota community, warranting future mechanistic and prospective longitudinal studies. Additionally, we were able to detect microbiome changes in patients who were re-infected with SARS-CoV-2. Notably, the dominant bacteria in the re-infected group were and , compared to the one-time infected group.
2019年冠状病毒病（COVID-19）会改变肠道微生物群。本研究旨在通过对粪便样本进行为期七个月的随访，评估COVID-19疾病严重程度与粪便微生物变化之间的关联。
我们对58例COVID-19患者和116例未感染对照进行了一项多中心、前瞻性纵向研究。使用16S核糖体RNA测序分析肠道微生物群的差异。首次粪便样本在COVID-19的早期康复阶段采集，第二次样本在COVID-19感染后至少七个月采集。
在目水平上，与对照组相比，COVID-19组中的[具体菌目1]和[具体菌目2]减少，而[具体菌目3]和[具体菌目4]增加。与对照组相比，COVID-19患者的α多样性也降低，七个月后肠道微生物群未完全恢复。中度和重度组在早期和晚期康复阶段之间肠道微生物群的组成变化最大。COVID-19的严重程度是微生物群组成最有影响的临床变量（平方和=0.686，P=0.006），即使在排除抗生素使用和年龄等其他影响因素后，其影响仍然存在。因此，我们的研究表明呼吸道病毒感染与肠道微生物群组成之间可能存在相互作用，值得未来进行机制和前瞻性纵向研究。此外，我们能够检测到再次感染SARS-CoV-2的患者的微生物群变化。值得注意的是，与一次性感染组相比，再次感染组中的优势菌是[具体细菌1]和[具体细菌2]。
